Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Sponsor
University of Wisconsin, Madison
Study ID
NCT00798720
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non Small Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • vorinostat — DRUG
    400 mg by mouth once daily for days 1-14 of each 21 day cycle
  • bortezomib — DRUG
    1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle

Study Details

The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.

Key Dates

Start date
Dec 31, 2008
Status verified
Sep 2016
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vorinostat + Bortezomib
    Vorinostat 400 mg + Bortezomib 1.3 mg/m2

Primary Outcome Measure

Three-month Progression-free Survival [ Time Frame: Three-months post-treatment ]

Related Studies